Cover Image
市場調查報告書

全球囊狀纖維化症治療藥市場(2016∼2026年):囊狀纖維化症薄膜傳導控制因子(CFTR)調整劑,蛋白質轉印調整劑,胰酵素產品(PEP),其他

Global Cystic Fibrosis Therapeutics Market 2016-2026: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies

出版商 Visiongain Ltd 商品編碼 410423
出版日期 內容資訊 英文 191 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球囊狀纖維化症治療藥市場(2016∼2026年):囊狀纖維化症薄膜傳導控制因子(CFTR)調整劑,蛋白質轉印調整劑,胰酵素產品(PEP),其他 Global Cystic Fibrosis Therapeutics Market 2016-2026: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies
出版日期: 2016年11月02日 內容資訊: 英文 191 Pages
簡介

全球囊狀纖維化症市場預計2016∼2021年以16.7%的年複合成長率擴大。該市場預計至2021年達到77億美元。

本報告提供全球囊狀纖維化症市場相關調查,市場概要和至2026年的預測,囊狀纖維化症薄膜傳導控制因子(CFTR)調整劑,蛋白質轉印調整劑,胰酵素產品(PEP)等的各市場區隔概要,及進入此市場的主要企業簡介等彙整資料。

第1章 本報告概要

第2章 囊狀纖維化症的簡介

  • 囊狀纖維化症概要
  • 囊狀纖維化症相關遺傳基因
  • 囊狀纖維化症相關新生兒篩檢
  • 徵兆與症狀
  • 診斷
  • 治療
  • 預後
  • 生活品質
  • 流行病學
  • 歐洲的流行病學趨勢
  • 加拿大的流行病學趨勢
  • 其他各國的流行病學趨勢

第3章 全球囊狀纖維化症市場:2016∼2026年

  • 各地區市場
  • 美國市場
  • 歐洲市場
  • 其他各國市場
  • 市場預測

第4章 各醫藥品類別市場

  • CFTR調整劑
  • 蛋白質轉印調整劑
  • Ceron,胰酵素產品(PEP)
  • 其他
  • 藥理學性級預測的互相比較

第5章 產品上市計劃,專利分析,交易分析

第6章 產品簡介:主要的治療藥

第7章 企業簡介

  • Vertex
  • Roche
  • AbbVie
  • Gilead Sciences
  • Novartis

第8章 囊狀纖維化症市場定性分析

  • 優勢
  • 弱點
  • 機會
  • 威脅
  • 政治因子
  • 經濟因子
  • 社會因子
  • 技術性因子

第9章 結論

第10章 用語

圖表

目錄
Product Code: PHA0151

The latest report from business intelligence provider visiongain offers comprehensive analysis of the global cystic fibrosis market. Visiongain expects the global cystic fibrosis market to grow at a CAGR of 16.7% from 2016 to 2021. The global cystic fibrosis market is estimated to reach $7.7bn by 2021.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this 191-page report you will receive 113 tables, charts and graphs - all unavailable elsewhere.

The 191 page report provides clear detailed insight into the global cystic fibrosis market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Cystic Fibrosis market forecasts from 2016-2026
  • Cystic Fibrosis submarket forecasts from 2016-2026 covering:
  • Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
  • Protein Transcription Modulators
  • Pancreatic Enzyme Products (PEP)
  • Other therapies
  • Individual drug revenue forecasts from 2016-2026 by pharmacological classes:
  • Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators:
    • Orkambi
    • Kalydeco
    • VX-661 + ivacaftor
    • Second corrector/VX-661/ivacaftor
  • Protein Transcription Modulators
    • Pulmozyme
    • QR-010
    • Translarna
  • Pancreatic Enzyme Products (PEP)
    • Ceron
  • Other therapies
    • Cayston
    • TOBI
  • Revenue forecasts from 2016-2026 and discussion of relevant trends and developments in the leading national cystic fibrosis market
  • Analysis of the key factors driving growth in the global, regional and country level of the Cystic Fibrosis Market from 2016-2026
  • Patent and clinical trials information of the marketed and pipeline products for cystic fibrosis
  • The dynamic of pricing, patient share and market share of the leading cystic fibrosis drugs in the US and Europe
  • Discussion on selected leading companies marketing and developing cystic fibrosis drugs:
    • Vertex Pharmaceuticals
    • Roche
    • AbbVie
    • Gilead Sciences
    • Novartis

Visiongain's study is intended for anyone requiring commercial analyses for the Cystic Fibrosis Market and leading companies. You find data, trends and predictions.

Buy our report today: Global Cystic Fibrosis Therapeutics Market 2016-2026: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Cystic Fibrosis Market Overview
  • 1.2. Why You Should Read This Report
  • 1.3. Structure of the Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report Include:
  • 1.6. Who is This Report For?
  • 1.7. Methodology
    • 1.7.1. Primary Research
    • 1.7.2. Secondary Research
    • 1.7.3. Market Evaluation & Forecasting Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated visiongain Reports
  • 1.10. About visiongain

2. Introduction to the Cystic Fibrosis Market

  • 2.1. An Overview of Cystic Fibrosis
  • 2.2. Genetics Associated With Cystic Fibrosis
    • 2.2.1. CFTR Chromosome Location
    • 2.2.2. CFTR Mutations
    • 2.2.3. Inheritance Pattern
  • 2.3. New-born Screening for Cystic Fibrosis
  • 2.4. Signs and Symptoms
    • 2.4.1. Respiratory Inflammation and Infections
    • 2.4.2. Gastrointestinal Tract Symptoms
    • 2.4.3. Fertility and Reproduction Related Issues
  • 2.5. Diagnosis
    • 2.5.1. Sweat Testing
    • 2.5.2. Nasal Potential Measurements Voltage
    • 2.5.3. Genotyping
    • 2.5.4. Ancillary Testing
  • 2.6. Treatment
    • 2.6.1. Gene Therapy
    • 2.6.2. Symptomatic Treatment
      • 2.6.2.1. Respiratory Care
      • 2.6.2.2. Inhaled Bronchodilators
      • 2.6.2.3. Airway Clearance
      • 2.6.2.4. Antibiotics
      • 2.6.2.5. Lung Transplant
      • 2.6.2.6. Other Treatments
  • 2.7. Prognosis
  • 2.8. Quality of Life
  • 2.9. Epidemiology
    • 2.9.1. Epidemiology Trends in the US
      • 2.9.1.1. Age Distribution of Cystic Fibrosis Patients in the US
  • 2.10. Epidemiology Trends in Europe
    • 2.10.1. Age Distribution of Cystic Fibrosis Patients in Europe
  • 2.11. Epidemiology Trends in Canada
  • 2.12. Epidemiology Trends in RoW
  • 2.13. Epidemiology Trends of F 508 Del Mutations

3. Global Cystic Fibrosis Market 2016-2026

  • 3.1. Cystic Fibrosis Regional Markets 2016-2026
    • 3.1.1. US Cystic Fibrosis Market Forecast 2016-2026
    • 3.1.1. Cost per Patient per Year (US)
    • 3.1.2. Price Increase of Cystic Fibrosis Drugs YoY (US)
    • 3.1.3. Patients Treated by Various Drugs (US)
    • 3.1.4. Patient Share vs Market Share of Top Products (US)
  • 3.2. Europe Cystic Fibrosis Market Forecast 2016-2026
  • 3.3. RoW Cystic Fibrosis Market Forecast 2016-2026
    • 3.3.1. Cystic Fibrosis Japan Market
  • 3.4. Cystic Fibrosis Regional Market Forecast 2016-2026

4. Cystic Fibrosis market - By Pharmaceutical class 2016-2026

  • 4.1. Cystic Fibrosis market - CFTR Modulators 2016-2026
    • 4.1.1. Orkambi (Vertex Pharmaceuticals) market - CFTR Modulators 2016-2026
    • 4.1.2. Kalydeco (Vertex Pharmaceuticals) market - CFTR Modulators 2016-2026
    • 4.1.3. VX-661 + ivacaftor (Royalty Pharma) market - CFTR Modulators 2016-2026
    • 4.1.4. Second corrector/VX-661/ivacaftor (Vertex Pharmaceuticals) market - CFTR Modulators 2016-2026
    • 4.1.5. Cross Comparison of CFTR Modulators Forecast 2016-2026
  • 4.2. Cystic Fibrosis market - Protein Transcription Modulators 2016-2026
    • 4.2.1. Pulmozyme (Roche) market - Protein Transcription Modulators 2016-2026
    • 4.2.2. QR-010 (ProQR Therapeutics) - Protein transcription Modulators 2016-2026
    • 4.2.3. Translarna (PTC Therapeutics) market - CFTR Modulators 2016-2026
    • 4.2.4. Cross Comparison of Protein Transcription Modulators Forecast 2016-2026
  • 4.3. Cystic Fibrosis market - Ceron (AbbVie), Pancreatic enzyme product (PEP) 2016-2026
  • 4.4. Cystic Fibrosis market - Other Therapies 2016-2026
    • 4.4.1. Cayston (Gilead Science) Market Forecast 2016-2026
    • 4.4.2. TOBI (Novartis) Market Forecast 2016-2026
  • 4.5. Cross Comparison of Pharmacological Class Forecast in CF 2016-2026

5. Timeline of Product Launches, Patent analysis and Deal analysis for Key Therapies

  • 5.1. Timeline of US Product Launches - Key Therapies
  • 5.2. Timeline of Europe Product Launches - Key Therapies
  • 5.3. Timeline of Japan Product Launches - Key Therapies
  • 5.4. Patent analysis in Cystic Fibrosis - Key Therapies
    • 5.4.1. Patent analysis of Launched Products - Key Therapies
    • 5.4.2. Patent analysis of Phase 3 Products - Key Therapies
    • 5.4.3. Patent analysis of Phase 2 Products - Key Therapies
    • 5.4.4. Patent analysis of Phase 1 Products - Key Therapies
    • 5.4.5. Patent analysis of pre-clinical and research stage products - Key Therapies
  • 5.5. Deal analysis in Cystic Fibrosis - Key Therapies

6. Product Profiles in Cystic Fibrosis - Key Therapies

  • 6.1. Orkambi (Vertex Pharmaceuticals) Product Profile
  • 6.2. Kalydeco (Vertex Pharmaceuticals) Product Profile
  • 6.3. Pulmozyme (Roche) Product Profile
  • 6.4. Translarna (PTC Therapeutics) Product Profile
  • 6.5. Tezacaftor (Vertex Pharmaceuticals) Product Profile
  • 6.6. Ivacaftor and tezacaftor (Vertex Pharmaceuticals) Combination Product Profile

7. Company Profiles

  • 7.1. Vertex Company Profile
    • 7.1.1. Vertex Company Overview
    • 7.1.2. Vertex Projects Overview
    • 7.1.3. Vertex Recent Deals
    • 7.1.4. Key Product sales (2010-2020)
  • 7.2. Roche Company Profile
    • 7.2.1. Roche Company Overview
    • 7.2.2. Roche Projects Overview
    • 7.2.3. Roche Recent Deals
    • 7.2.4. Roche Key Product sales
  • 7.3. AbbVie Company Profile
    • 7.3.1. AbbVie Company Overview
    • 7.3.2. AbbVie Projects Overview
    • 7.3.3. AbbVie Recent Deals
    • 7.3.4. AbbVie Key Product Sales
  • 7.4. Gilead Sciences Company Profile
    • 7.4.1. Gilead Company Overview
    • 7.4.2. Gilead Projects Overview
    • 7.4.3. Gilead Recent Deals
    • 7.4.3. Gilead Key Product Sales
  • 7.5. Novartis Company Profile
    • 7.5.1. Novartis Company Overview
    • 7.5.2. Novartis Projects Overview
    • 7.5.3. Novartis Recent Deals
    • 7.5.3. Novartis Key Product Sales

8. Qualitative Analysis of the Cystic Fibrosis Market

  • 8.1. Strengths of the Cystic Fibrosis Market
  • 8.2. Weaknesses of the Cystic Fibrosis Market
  • 8.3. Opportunities for the Cystic Fibrosis Market
  • 8.4. Threats for the Cystic Fibrosis Market
  • 8.5. Political Factors Influencing the Cystic Fibrosis Market
  • 8.6. Economical Factors Influencing the Cystic Fibrosis Market
  • 8.7. Social Factors Influencing the Cystic Fibrosis Market
  • 8.8. Technological Factors Influencing the Cystic Fibrosis Market

9. Conclusions

  • 9.1. Cost of Therapies in Cystic Fibrosis
  • 9.2. Patient vs Market Share Trends in Cystic Fibrosis
  • 9.3. Global Cystic Fibrosis Market Trends from 2016 to 2026
  • 9.4. Geographical trends of Cystic Fibrosis Market
  • 9.5. Cystic Fibrosis Market as per Pharmacological Class

10. Glossary

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Figures:

  • Figure 1: Functional Difference in Normal and Cystic Fibrosis Lung Cells
  • Figure 2: CFTR Chromosome Location
  • Figure 3: Sweat Testing
  • Figure 4: Median Predicted Survival Age for Patients Born with Cystic Fibrosis
  • Figure 5: Worldwide Disease Prevalence of Cystic Fibrosis, 2016 - 2026
  • Figure 6: US Disease Prevalence of Cystic Fibrosis, 2016 - 2026
  • Figure 7: Age Distribution of Patients with Cystic Fibrosis in the US, 2016
  • Figure 8: Age Distribution (%) of Patients with Cystic Fibrosis in the US, 2016
  • Figure 9: Epidemiology Trends of Patients with Cystic Fibrosis in Europe, 2016 - 2026
  • Figure 10: Age Distribution of Patients with Cystic Fibrosis in Europe, 2016
  • Figure 11: Age Distribution (%) of Patients with Cystic Fibrosis in Europe, 2016
  • Figure 12: Epidemiology Trends of Patients with Cystic Fibrosis in Canada, 2016 - 2026
  • Figure 13: Prevalence Rate of Cystic Fibrosis by Region, 2016
  • Figure 14: F 508 Del Mutation Spread US, 2016
  • Figure 15: F 508 Del Mutation Spread Europe, 2016
  • Figure 16: Worldwide Cystic Fibrosis Market, 2016-2026
  • Figure 17: Cystic Fibrosis Regional Market Split, 2016
  • Figure 18: Cystic Fibrosis Regional Market Split, 2021
  • Figure 19: Cystic Fibrosis Regional Market Split, 2026
  • Figure 20: US Cystic Fibrosis Market Forecasts, 2016-2026
  • Figure 21: Cost per Patient per Year in the US, 2016
  • Figure 22: YoY Price Growth of Top Cystic Fibrosis Products, 2016
  • Figure 23: Patients Treated by Various Cystic Fibrosis Drugs, 2016
  • Figure 24: Patients Share Captured in the US by Various Drugs, 2016
  • Figure 25: Market Share Captured in the US by Various Drugs, 2016
  • Figure 26: Europe Cystic Fibrosis Market Forecasts, 2016-2026
  • Figure 27: RoW Cystic Fibrosis Market Forecasts, 2016-2026
  • Figure 28: Comparative Cystic Fibrosis Market Forecasts by Region, 2016-2026
  • Figure 29: CFTR Modulators Market Forecasts, 2016-2026
  • Figure 30: Orkambi (Vertex Pharmaceuticals) Market Forecasts, 2016-2026
  • Figure 31: Kalydeco (Vertex Pharmaceuticals) Market Forecasts, 2016-2026
  • Figure 32: VX-661 + ivacaftor (Royalty Pharma) Market Forecasts, 2016-2026
  • Figure 33: Second corrector/VX-661/ivacaftor (Vertex Pharmaceuticals) Market Forecasts, 2016-2026
  • Figure 34: Comparative CFTR Modulators Market Share (%), 2021
  • Figure 35: Comparative CFTR Modulators Market Share (%), 2026
  • Figure 36: Comparative CFTR Modulators Market Forecast projections ($m), 2016 - 2026
  • Figure 37: Protein Transcription Modulators Market Forecasts ($m), 2016-2026
  • Figure 38: Pulmozyme (Roche) Market Forecasts ($m), 2016-2026
  • Figure 39: QR-010 Market Forecasts ($m), 2016-2026
  • Figure 40: Translarna Market Forecasts ($m), 2016-2026
  • Figure 41: Comparative Protein Transcription Modulators Market Share (%), 2016
  • Figure 42: Comparative Protein Transcription Modulators Market Share (%), 2021
  • Figure 43: Comparative Protein Transcription Modulators Market Share (%), 2026
  • Figure 44: Comparative Protein Transcription Modulators Market Forecast Projections, 2016 - 2026
  • Figure 45: Ceron (AbbVie) Market Forecasts ($m), 2016-2026
  • Figure 46: Cayston (Gilead Science) Market Forecasts ($m), 2016-2026
  • Figure 47: TOBI (Novartis) Market Forecasts ($m), 2016-2026
  • Figure 48: Comparative Pharmacological Class Market Share (%), 2016
  • Figure 49: Comparative Pharmacological Class Market Share (%), 2021
  • Figure 50: Comparative Pharmacological Class Market Share (%), 2026
  • Figure 51: Comparative Forecast Assessment by Pharmacological Class ($m), 2016 - 2026
  • Figure 52: Deal Count in CF 2000-2015
  • Figure 53: Vertex Project Overview by Development Stage
  • Figure 54: Vertex Project Overview by Therapeutic Area
  • Figure 55: Vertex Licensing and Acquisition Deals, 2009-2016
  • Figure 56: Vertex Key Product Sales (Historic and Forecasted), 2010-2020
  • Figure 57: Roche Project Overview by Development Stage
  • Figure 58: Roche Deal Count, 2010-2016
  • Figure 59: Roche Key Product Sales (Historic and Forecasted), 2010-2020
  • Figure 60: AbbVie Project Overview by Development Stage
  • Figure 61: AbbVie Deal Count, 2010-2016
  • Figure 62: AbbVie Key Product Sales (Historic and Forecasted), 2010-2020
  • Figure 63: Gilead Project Overview by Development Stage
  • Figure 64: Gilead Deal Count, 2010-2016
  • Figure 65: Gilead Key Product Sales (Historic and Forecasted), 2010-2020
  • Figure 66: Novartis Deal Count, 2010-2016
  • Figure 67: Novartis Key Product Sales (Historic and Forecasted), 2010-2020

List of Tables:

  • Table 1: Classes of CFTR Mutations
  • Table 2: Symptoms of Cystic Fibrosis
  • Table 3: Cystic Fibrosis Foundation Guidelines for Cystic Fibrosis Care
  • Table 4: Worldwide Cystic Fibrosis Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 5: US Cystic Fibrosis Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 6: Patients Treated by Various Cystic Fibrosis Drugs in the US, 2016
  • Table 7: Europe Cystic Fibrosis Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 8: RoW Cystic Fibrosis Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 9: Comparative CF Market Forecasts by Region: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 10: CFTR Modulators Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 11: Orkambi (Vertex Pharmaceuticals) Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 12: Kalydeco (Vertex Pharmaceuticals) Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 13: VX-661 + ivacaftor (Royalty Pharma) Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 14: Second corrector/VX-661/ivacaftor (Vertex Pharmaceuticals) Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 15: Comparative CFTR Modulators Market Forecasts: Revenues ($m), AGR (%), CAGR (%)
  • Table 16: Protein transcription modulators Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 17: Pulmozyme (Roche) Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 18: QR-010 Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 19: Translarna Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 20: Comparative Protein Transcription Modulators Market Forecasts by Region: Revenue ($m), AGR (%), CAGR (%), 2016-2026Region: Revenue ($m), AGR (%), CAGR (%), 2016-2026
  • Table 21: Ceron (AbbVie) Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 22: Cayston (Gilead Science) Market Forecasta: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 23: TOBI (Novartis) Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 24: Comparative Protein Transcription Modulators Market Forecasts by Region: Revenues ($m), AGR (%), CAGR (%), 2016-2026
  • Table 25: US Product Launch - Key Therapies
  • Table 26: Europe Product Launch - Key Therapies
  • Table 27: Japan Product Launch - Key Therapies
  • Table 28: Patent analysis of Launched Products - Key Therapies
  • Table 29: Patent analysis of Phase 3 Products - Key Therapies
  • Table 30: Patent analysis of Phase 2 Products - Key Therapies
  • Table 31: Patent analysis of Phase 1 Products - Key Therapies
  • Table 32: Patent analysis of pre-clinical/research stage Products - Key Therapies
  • Table 33: Deal trend analysis in CF - 2000-2015
  • Table 34: Vertex Company Overview
  • Table 35: Vertex Key M&As
  • Table 36: Roche Company Overview
  • Table 37: Roche Key Deals
  • Table 38: AbbVie Company Overview
  • Table 39: AbbVie Key Deals
  • Table 40: Gilead Company Overview
  • Table 41: Gilead Key Deals
  • Table 42: Novartis Company Overview
  • Table 43: Novartis Key Deals
  • Table 44: Strengths and Weakness of the Cystic Fibrosis Market
  • Table 45: Opportunities and Threats for the Cystic Fibrosis Market
  • Table 46: Political, Economic, Social and technological Factors influencing Cystic Fibrosis Market

Companies Listed

  • AbbVie
  • Aradigm
  • Aurora Biosciences
  • Bayer
  • Celtaxsys
  • Chiesi
  • Chugai Pharmaceutical Co.
  • Concert Pharmaceuticals
  • Corbus Pharmaceuticals
  • Cyclacel Pharmaceuticals
  • Demegen
  • EmphyCorp
  • EryDel
  • FDA
  • Genentech
  • Genkyotex
  • Gilead
  • InDex Pharmaceutials
  • ManRos Therapeutics
  • NanoBio
  • NICE
  • NIH
  • Novartis
  • Novoteris
  • Ocean Therapeutics
  • OrPro Therapeutics
  • Polydex Pharmaceuticals
  • ProQR Therapeutics
  • Pulmatrix
  • Roche
  • Shire
  • Teva
  • The University of Iowa
  • The University of Wisconsin
  • The University of Wisconsin System
  • UCB
  • University of Maryland
  • Vectura
  • Vertex Pharmaceuticals
  • ViroChem Pharma
  • XOMA
Back to Top